Healthy volunteers test new compound for brain disorders
NCT ID NCT05938452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a compound called glyceryl tribenzoate (GTB) in 40 healthy adults aged 18 to 50. Participants received either a single or multiple doses of GTB or a placebo. The goal was to check for side effects and how the body processes the drug, not to treat any disease. Results will help decide if GTB should be studied further for neurological conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TKL Research
Bloomfield, New Jersey, 07003, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain health boost: yoga, music, and diet may ward off neurological disorders
- Bedtime stories for autism? Single-Child trial shows early gains
- Study pits two MG drugs Head-to-Head in everyday practice
- Could a portable MRI replace bulky scanners for brain checks?
- Could fitness trackers replace fancy lab gear for walking problems?
- Mind-Controlled tech trial launches for ALS patients